Company Overview and News
KUALA LUMPUR: JF Apex Research expects Sapura Energy Bhd , Cahya Mata Sarawak Bhd (CMSB), Southern Steel Bhd , Dayang Enterprise Holdings Bhd and Axiata Group Bhd to be among the stocks to watch on Monday.
4634 2852 0146 5665 6888 5141 AXXTF 7155
KUALA LUMPUR (Aug 24): Based on corporate announcements and news flow today, companies that will be in focus on Monday (Aug 27) may include: Sapura Energy Bhd, PUC Bhd, Axiata Group Bhd, Cahya Mata Sarawak Bhd, Magnum Bhd, Southern Steel Bhd, Dayang Enterprise Holdings Bhd, SKP Resources Bhd, MMC Corp Bhd, MSM Malaysia Holdings Bhd, Pos Malaysia Bhd, Paramount Corp Bhd and Adventa Bhd.
4634 2852 5665 6888 IDEA 5141 ICLQY AXXTF 5202 532822 7155
KUALA LUMPUR (Aug 24): Southern Steel Bhd’s fourth quarter net profit grew by more than six times to RM35.21 million from RM5.57 million a year earlier, on higher sales volume and net margin.
5665 BSMAF 1818
KUALA LUMPUR (Aug 13): Malaysia's steel sector is likely to experience further headwinds, as global demand is likely to be further hit by shaky demand from China's waning construction sector, in addition to risks from trade war tariffs, said MIDF Amanah Investment Bank Bhd Research.
5797 5665 6556 5094 5087 9199
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...